颈项透明层增厚胎儿的微阵列检测与RASopathy疾病检测
该回顾性研究纳入226例颈项透明层厚度≥3.5 mm的妊娠,QF-PCR检出51.3%染色体非整倍体,剩余110例中染色体核型/微阵列检出8.2%异常,RASopathy检测检出率2.9%,最佳NT截断值为7.9 mm,遗传检测联合超声可影响妊娠结局。
要点
- NT≥3.5 mm时QF-PCR检出51.3%染色体非整倍体。
- 剩余病例中染色体核型/微阵列异常检出率8.2%,RASopathy致病性变异检出率2.9%。
- 该人群RASopathy筛查最佳NT截断值为7.9 mm。
核心结论
- CMA和RASopathy分子检测均为NT≥3.5 mm妊娠的重要检查。
- 遗传检测联合胎儿超声检查可提供影响妊娠结局及再发风险的有价值信息。
研究设计与样本
- 回顾性病历审查,纳入2013年1月至2015年12月转诊至西奈山医院产前诊断与医学遗传学项目的NT≥3.5 mm且行绒毛膜绒毛取样或羊膜腔穿刺的患者,共226例。
主要发现
- QF-PCR在116/226(51.3%)例中检出染色体非整倍体。
- 剩余110/226(48.7%)例进一步遗传检测,核型/CMA在9/110(8.2%)例检出异常/致病性细胞遗传学结果,另有5例意义不明变异。
- RASopathy检测在103例中检出3例致病性变异,检出率2.9%,另有1例意义不明变异。
- 该人群RASopathy筛查最佳NT截断值为7.9 mm。
- 遗传学检查正常的110例中,92/110(83.6%)例结果正常;其中孕14-16周详细胎儿超声发现结构异常24例(26.1%),孕18-22周详细超声异常15例(16.3%),胎儿超声心动图发现心脏异常9例(9.8%)。
关键数值与推荐
- NT≥3.5 mm为纳入标准。
- QF-PCR作为非整倍体一线检测;结果阴性者行核型分析和/或CMA;结果正常者行RASopathy致病性变异检测(包含9个已知基因)。
临床怎么用
- 作者提出对NT≥3.5 mm患者采用遗传检测联合胎儿超声检查的临床方案。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To determine the incidence of chromosomal abnormalities, submicroscopic chromosomal abnormalities and RASopathy-disorder (RD) pathogenic variants in a cohort of pregnancies with nuchal translucency thickness (NT) ≥ 3.5 mm, and to propose a clinical protocol for surveillance of this group of patients. METHODS: This was a retrospective chart review of patients referred to The Prenatal Diagnosis and Medical Genetics Program at Mount Sinai Hospital between January 2013 and December 2015, due to NT ≥ 3.5 mm, who underwent chorionic villus sampling or amniocentesis. Patients underwent extensive genetic counseling prior to invasive procedures and testing. Quantitative fluorescence polymerase chain reaction (QF-PCR) was performed as the first-line test for aneuploidy. If the result was negative, patients underwent karyotyping and/or chromosomal microarray analysis (CMA), and if the findings were normal, they had testing for RD pathogenic variants, which included nine known genes. Patients also underwent detailed fetal ultrasound examinations and echocardiography, performed by expert operators. RESULTS: A total of 226 eligible patients were identified. In 116/226 (51.3%) patients, QF-PCR identified a chromosomal aneuploidy. The remaining 110/226 (48.7%) patients had further genetic testing. Karyotyping/CMA detected an abnormal/pathogenic cytogenetic result in 9/110 (8.2%) patients, as well as five variants of unknown significance (VOUS). RD testing yielded three pathogenic variants (3/103), giving a detection rate of 2.9%, and one VOUS. The optimal NT cut-off for RD screening was 7.9 mm in this population. In 92/110 (83.6%) patients, the genetic investigations were normal. Of these pregnancies, an early (14-16 weeks' gestation) detailed fetal ultrasound examination identified a structural abnormality in 24 (26.1%), 15 (16.3%) had an abnormal detailed ultrasound examination at 18-22 weeks' gestation and fetal echocardiography showed a cardiac abnormality in nine (9.8%). The birth outcome in the 83 pregnancies that had normal genetic investigations and known outcome included seven (8.4%) cases of termination of pregnancy, seven (8.4%) cases of intrauterine fetal death and 69 (83.1%) cases of live birth. Nine (9.8%) patients were lost to follow-up. CONCLUSIONS: Both CMA and molecular testing for RD are important investigations in pregnancies with NT ≥ 3.5 mm. The use of genetic testing combined with fetal ultrasound examination provides valuable information that can influence pregnancy outcome, and provide recurrence risks, in this patient population. Copyright © 2019 ISUOG. Published by John Wiley & Sons Ltd.
引用
- Sinajon P, Chitayat D, Roifman M, et al. Microarray and RASopathy-disorder testing in fetuses with increased nuchal translucency. Ultrasound Obstet Gynecol. 2020. PMID: 31115076. doi:10.1002/uog.20352
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。